Biomarker panel identified prostate cancer with 90% accuracy

Harris, Jason; Southall, Jennifer
October 2010
Hem/Onc Today;10/25/2010, Vol. 11 Issue 20, p20
The article discusses research being done on the use of biomarkers for detecting prostate cancer and prostate disease, which references a study by John Anson and colleagues presented at the American Association for Cancer Research (AACR) International Conference in Denver, Colorado from September 27-30, 2010.


Related Articles

  • PCa biomarkers under investigation.  // Urology Times;Oct2002, Vol. 30 Issue 10, p32 

    Lists prostate cancer biomarkers being investigated in the U.S., current as of October 2002. Hepsin; Caveolin 1; RNase L; Human glandular kallikrein.

  • Bloodborne biomolecular markers in prostate cancer development and progression. Bok, Robert A.; Small, Eric J. // Nature Reviews Cancer;Dec2002, Vol. 2 Issue 12, p918 

    Prostate cancer is notoriously difficult to treat, which makes its early detection a priority. Biomarkers have been used to diagnose and monitor prostate cancer for more than 50 years, and the discovery of the serum marker prostate-specific antigen (PSA) significantly altered the detection and...

  • New biomarkers may detect PCa precursor lesions. Prescott, Lawrence M. // Urology Times;May2001, Vol. 29 Issue 5, p11 

    Reports on the identification of biomarkers that may help in predicting prostate cancer. Potential markers including morphologic entities such as high-grade prostatic intraepithelial neoplasia and other markers that can be analyzed by immunochemistry; Hypothetical model suggesting that the...

  • Incorporating monotonicity into the evaluation of a biomarker. Debashis Ghosh // Biostatistics;Apr2007, Vol. 8 Issue 2, p402 

    In the assessment of clinical utility of biomarkers, case–control studies are often undertaken based on existing serum samples. A common assumption made in these studies is that higher levels of the biomarker are associated with increased disease risk. In this article, we consider methods...

  • ANX7 as a bio-marker in prostate and breast cancer progression. Srivastava, Meera; Bubendorf, Lukas; Nolan, Lisa; Glasman, Mirta; Leighton, Ximena; Miller, Georgina; Fehrle, Wilfred; Raffeld, Mark; Eidelman, Ofer; Kallioniemi, Olli P.; Srivastava, Shiv; Pollard, Harvey B. // Disease Markers;2001, Vol. 17 Issue 2, p115 

    The ANX7 gene codes for a Ca

  • Altered PCA3 and TMPRSS2-ERG expression in histologically benign regions of cancerous prostates: a systematic, quantitative mRNA analysis in five prostates. Väänänen, Riina-Minna; Ochoa, Natalia Tong; Boström, Peter J.; Taimen, Pekka; Pettersson, Kim // BMC Urology;Aug2015, Vol. 15 Issue 1, p1 

    Background: PCA3 and TMPRSS2-ERG are commonly overexpressed biomarkers in prostate cancer, but reports have emerged demonstrating altered expression also in areas outside the tumour foci in cancerous prostates. Our aim was to measure PCA3 and TMPRSS2-ERG expression systematically in all regions...

  • Cancer Epidemiology, Biomarkers & Prevention: Genetic link to prostate cancer risk in African Americans found.  // Biomedical Market Newsletter;8/28/2012, Vol. 21, p1 

    The article informs that changes in the Interleukin-16 gene leads to the discovery of a biomarker for the diagnosis of prostate cancer.

  • Treatment outcome of high-dose image-guided intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer at a single institute in Japan. Takeda, Ken; Takai, Yoshihiro; Narazaki, Kakataro; Mitsuya, Masatoshi; Umezawa, Rei; Kadoya, Noriyuki; Fujita, Yukio; Sugawara, Toshiyuki; Kubozono, Masaki; Shimizu, Eiji; Abe, Keiko; Shirata, Yuko; Ishikawa, Yohjiro; Yamamoto, Takaya; Kozumi, Maiko; Dobashi, Suguru; Matsushita, Haruo; Chida, Koichi; Ishidoya, Shigeto; Arai, Yoichi // Radiation Oncology;2012, Vol. 7 Issue 1, p105 

    Background: Several studies have confirmed the advantages of delivering high doses of external beam radiotherapy to achieve optimal tumor-control outcomes in patients with localized prostate cancer. We evaluated the medium-term treatment outcome after high-dose, image-guided intensity-modulated...

  • Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. Sun, Shihua; Sprenger, Cynthia C. T.; Vessella, Robert L.; Haugk, Kathleen; Soriano, Kathryn; Mostaghel, Elahe A.; Page, Stephanie T.; Coleman, Ilsa M.; Nguyen, Holly M.; Sun, Huiying; Nelson, Peter S.; Plymate, Stephen R. // Journal of Clinical Investigation;Aug2010, Vol. 120 Issue 8, p2715 

    Progression of prostate cancer following castration is associated with increased androgen receptor (AR) expression and signaling despite AR blockade. Recent studies suggest that these activities are due to the generation of constitutively active AR splice variants, but the mechanisms by which...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics